Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study


13 Apr 2018


New approaches in rare thoracic tumors


Nick Pavlakis


Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.


N. Pavlakis1, F. Grosso2, N. Steele3, A. Nowak4, S. Novello5, S. Popat6, L. Greillier7, M. Reck8, T. Kitzing9, G. Scagliotti5

Author affiliations

  • 1 Northern Cancer Institute, 2065 - St Leonards/AU
  • 2 Department Of Oncology, SS Antonio e Biagio Hospital, Alessandria/IT
  • 3 The Beatson West of Scotland Cancer Centre, Glasgow/GB
  • 4 School Of Medicine, Faculty Of Medicine And Health Sciences, University of Western Australia, Crawley/AU
  • 5 Department Of Oncology, S. Luigi Hospital, University of Turin, Torino/IT
  • 6 Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 7 Assistance Publique - Hôpitaux de Marseille, Aix Marseille University, Marseille/FR
  • 8 Department Of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf/DE
  • 9 Boehringer Ingelheim Pharma GmbH & Co KG, Biberach/DE


The randomised Phase II/III LUME-Meso study is evaluating nintedanib + pemetrexed/cisplatin versus placebo + pemetrexed/cisplatin (≤6 cycles), followed by nintedanib or placebo maintenance, in chemo-naïve MPM. In the Phase II part, nintedanib treatment led to improved progression-free survival (PFS; hazard ratio [HR] = 0.54; p = 0.010) and a trend for longer overall survival (OS; HR = 0.77; p = 0.319) compared with placebo. Patients with epithelioid tumours derived greatest benefit. Plasma angiogenic factors and genomic markers were explored for potential associations with treatment outcome in the Phase II epithelioid population.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings